Ex­clu­sive: Bat­tle with ‘un­drug­gable’ can­cer tar­get be­ta-catenin heats up, as Sapi­ence dos­es first pa­tient

An­oth­er biotech start­up has en­tered the clin­ic with a shot at one of the biggest, most elu­sive cul­prits be­hind can­cer.

New York-based Sapi­ence Ther­a­peu­tics said …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER